We are excited to share that the University City Science Center and CSL Behring have partnered to identify and commercialize promising new technologies at research and academic institutions across the region. The Australian-based global biotechnology leader will leverage the Science Center’s expertise and the promising research being developed at institutions like yours to build its pipeline and broaden collaborative networks across the United States.

 

Researchers at institutions participating in the Science Center’s QED Program throughout the region are invited to submit proposals for research projects, as outlined below. Selected projects will receive a total of up to $300,000 in research funding from CSL Behring, together with scientific and in-kind support including reagent generation and consultancy on drug development strategy. The awards will be for a period of two years.

 

Timeline and Information:

 

• October 22, 2018: Opening Day for White Paper Submissions (nonconfidential, brief 1-2 page project descriptions). Submit to: Partnerships@sciencecenter.org

• December 14, 2018: Deadline for receipt of white paper applications.

• December 21, 2018: Notification on final applications to submit a full proof-of-concept grant proposal.

• January 22, 2019: Proof-of-concept grant proposals due from finalists to the Science Center.

 

Areas of Interest to CSL

 

Therapeutic Areas:

• Inflammatory and autoimmune diseases

• Hematological and coagulation disorders

• Transplantation

• Cardiovascular and metabolic diseases

• Respiratory diseases

• Neurological disorders

 

Modalities*:

• Protein/antibody based therapeutics

• Gene-based therapy

• Cell-based therapy

• Small molecules

• Translational Medicine

 

Technologies*:

• Protein characterization

• Protein/ vector manufacturing

• Drug delivery

 

*Modalities and Technologies must relate to a listed Therapeutic Area(s)